Table: Otsuka Holdings -Q1 group results (IFRS)
May 12 (Reuters)-
Otsuka Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2023 Mar 31, 2022 Dec 31, 2023
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 448.34 380.31 1.80 trln
(+17.9 pct) (+12.9 pct) (+3.6 pct)
Operating 76.78 20.75 210.00
(+270.0 pct) (-58.6 pct) (+39.7 pct)
Pretax
Net 61.43 23.25 157.50
(+164.2 pct) (-48.0 pct) (+17.6 pct)
EPS Basic 113.20 yen 42.86 yen 290.25 yen
EPS Diluted 113.18 yen 42.70 yen
Ann Div 100.00 yen 100.00 yen
-Q2 Div 50.00 yen 50.00 yen
-Q4 Div 50.00 yen 50.00 yen
NOTE - Otsuka Holdings Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4578.T
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug